ir.unither.comUnited Therapeutics Investor Relations

We do the right thing Our vision and mission are one.About United Therapeutics Leadership History Pioneers Locations & Subsidiaries Events Contact Us Corporate Corporate Responsibility Public Benefit Corporation Corporate Giving Research & Medicine Medicines for Life Addressing the needs of patients with chronic and life-threatening diseases.Our Medicines Remodulin ® Tyvaso ® | Tyvaso DPI ® Orenitram ® Adcirca ® Unituxin ® End-Stage Lung Disease LBE 360° Transplant Support Service Science Therapeutics Areas Clinical Trials Pipeline Medical Professionals At UT, this is personal Support for optimal patient care.Science and Medical Affairs About Science and Medical Affairs Scientific Library Sponsorships and Grants Investigator Sponsored Studies Jenesis Awards Program ™ Medical Education Grants and Scientific Sponsorships Commercial Product - Resources and Support Archways Educational Resource and Support Program iAssist Specialty Therapy Initiation Platform PAH Initiative Regional Nurse Specialist Team UT ASSIST Patients Support & Resources Support Programs Education PAH Support Group Meeting Requests Safety Initiatives Patient Organizations Global Product Safety and Pharmacovigilance Careers Unitherian We are bold and unconventional. We have fun, we do good.Careers at Unither To be a Unitherian Search For Job Benefits & Amenties Diversity & Inclusion Company Values and Policies Equal Opportunity Employer Recruitment Fraud Warning Awards & Recognitions Corporate Site Investors InvestorsInvestor Resources Corporate Governance Contact IR FAQ InvestorsInvestor Resources Corporate Governance Contact IR FAQ Investors Quick Links SEC Filings Events and Presentations CORPORATE PRESENTATION Press Releases Corporate Responsibility Contact IR Onward! United Therapeutics (Nasdaq: UTHR ) seeks to travel down the corridors of indifference to develop treatments for rare, deadly diseases. We were founded in 1996 by a family seeking a cure for their daughter’s pulmonary arterial hypertension, or PAH . Today, we have six FDA-approved therapies that treat PAH, pulmonary hypertension associated with interstitial lung disease ( PH-ILD ), and neuroblastoma, a rare pediatric cancer. Our near-term pipeline seeks to develop additional therapies for PAH and pulmonary fibrosis ( PF ). The cure for end-stage life-threatening diseases like PAH, PH-ILD, PF, and many others is an organ transplant, but only a small percentage of donated organs are available to address the vast need. For this reason, we are working to create manufactured organs to address the shortage of kidneys, hearts, lungs, and livers available for transplant. We believe an unlimited supply of tolerable, transplantable organs will eliminate the transplant waiting list and cure end-stage organ diseases for which transplant is not currently an option. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies; and technologies that expand the availability of transplantable organs. - Corporate Presentation August 2023 We invite you to download our corporate presentation to help understand our unique purpose, our current commercial footprint, and our innovative pipeline. Download our corporate presentation - Corporate Responsibility Report Covering our activities in 2022 As a public benefit corporation, we are obligated to manage and report our progress toward our public benefit purpose. We pursue this purpose alongside our obligations to address the interests of our other stakeholders — employees, local communities, investors, and the greater ecosystem in which we operate. In our report, we detail our progress against our public benefit goals and objectives, aligned with our three core stakeholder groups — what we call Our Patients, Our People, and Humankind. Download the report Go to our Corporate responsibility site Press Releases 01 May 2024 United Therapeutics Corporation Reports First Quarter 2024 Financial Results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.(BUSINESS WIRE) United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31,... Download pdf 24 Apr 2024 United Therapeutics Announces World’s First Successful Xenothymokidney Transplant The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplantThis transplant builds on two successful UHeart transplants completed in 2022 and... Download pdf 24 Apr 2024 United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.(BUSINESS WIRE) United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market... Download pdf 16 Apr 2024 United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion sessionAn annual update of the preliminary baseline data from the TETON phase 3... Download pdf 26 Mar 2024 United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation Review manuscript available in the journal Physiological Reviews SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.(BUSINESS WIRE) United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation... Download pdf 25 Mar 2024 United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospectsSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.(BUSINESS WIRE) United Therapeutics Corporation... Download pdf view all Investor Email Alerts sign up Products Pipeline Patients Careers Investors Corporate Responsibility Our Company Follow Us Terms and Conditions Privacy Policy Cookie Settings © 2023 - United Therapeutics All rights...